Book chapter · 2024 · Open access
15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19
Springer eBooks, 355–373 · Published 31 August 2024 · DOI 10.1007/978-3-031-48408-7_19
In brief
“15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19” is a 2024 book chapter by David N. Wholley and 2 co-authors, published in Springer eBooks. OpenAlex counts 3 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Springer eBooks.
- Citations
- 3
- Most cited in
- 2026 (2)
- Field-weighted impact
- 4.11
- References
- 17
- Authors
- 3
Abstract
In March 2020, as the threat of the oncoming coronavirus disease 2019 (COVID-19) pandemic became clearer, officials of the U.S. National Institutes of Health (NIH) and the Foundation for NIH (FNIH) rushed to put together a government-industry-academia coalition to promote and coordinate research to counter the virus. The resulting structure—called ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) soon included eight U.S. government agencies, 20 biopharmaceutical companies and several nonprofit organizations. Early on, ACTIV leaders organized their mission into four working groups of selected scientists: a Preclinical Working Group to evaluate the status of ongoing preclinical research, such as animal studies; a Clinical Therapeutics Working Group to screen potential drug candidates, prioritize them for further study, and then coordinate clinical trials for safety and efficacy; a Clinical Trial Capacity Working Group, to identify and qualify potential clinical trial sites; and a Vaccines Working Group, to harmonize ongoing vaccine trials and ensure robust determination of safety and efficacy. ACTIV replaced a plethora of small individual trials—many too small or insufficiently well designed to produce meaningful results—with a national research agenda for developing therapeutic countermeasures to a rapidly emerging infectious disease. ACTIV provides a model for how medical research can be effectively coordinated in a country without a centralized health system.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wholley, D. N., Collins, F. S., & Stoffels, P. (2024). 15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19. Springer eBooks, 355–373. https://doi.org/10.1007/978-3-031-48408-7_19
MLA 9
Wholley, David N., et al. “15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19.” Springer eBooks, 2024, pp. 355–373. https://doi.org/10.1007/978-3-031-48408-7_19.
Chicago
Wholley, David N., Francis S. Collins, and Paul Stoffels. 2024. “15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19.” Springer eBooks: 355–373. https://doi.org/10.1007/978-3-031-48408-7_19.
Harvard
Wholley, D. N., Collins, F. S. and Stoffels, P. (2024) ‘15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19’, Springer eBooks, pp. 355–373. doi:10.1007/978-3-031-48408-7_19.
IEEE
D. N. Wholley, F. S. Collins, and P. Stoffels, “15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19,” Springer eBooks, pp. 355–373, 2024, doi: 10.1007/978-3-031-48408-7_19.
BibTeX
@incollection{wholley2024activ,
title = {{15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19}},
author = {Wholley, David N. and Collins, Francis S. and Stoffels, Paul},
booktitle = {Springer eBooks},
publisher = {Springer Nature},
year = {2024},
pages = {355--373},
doi = {10.1007/978-3-031-48408-7_19},
url = {https://doi.org/10.1007/978-3-031-48408-7_19}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- COVID-19 pandemic
- public-private partnerships
- research coordination
- drug repurposing
- clinical trials
- vaccine development
- National Institutes of Health
- pandemic response
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Wholley, D. N., Collins, F. S., & Stoffels, P. (2024). 15 ACTIV: A U.S. Public-Private Partnership Responds to COVID-19. Springer eBooks, 355–373. https://doi.org/10.1007/978-3-031-48408-7_19
How many times has this paper been cited?
3 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Springer eBooks: sign in and open the PDF from this page.
Who wrote this paper?
David N. Wholley, Francis S. Collins, Paul Stoffels.
What is the DOI of this paper?
10.1007/978-3-031-48408-7_19, permanently at https://doi.org/10.1007/978-3-031-48408-7_19. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.